MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases
Jul 27, 2020•almost 5 years ago
Amount Raised
$34 Million
Round Type
series a
Description
MBX Biosciences, a drug discovery company focused in rare endocrine diseases, today announced the closing of a $34.6 million Series A financing. The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads) and Twilight Venture Partners II.
FundzWatch™ Score
65
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech